SRP-001: redefining pain treatment with a safer, non-opioid analgesic
Drug Target Review
JULY 1, 2024
SRP-001 targets the central nervous system (CNS) by producing N-arachidonoylaminophenol (AM404) in the midbrain’s periaqueductal grey (PAG) region, crucial for pain sensation and regulation. was founded in 2016 to develop safer, non-opioid therapies for acute and chronic pain. South Rampart Pharma, Inc.
Let's personalize your content